Cholinesterase inhibitors remain the long-standing pharmacologic standard in Alzheimer's disease, yet their measured effect on cognition is modest and does not alter the underlying course of neurodegeneration. The distinction between temporarily supporting neurotransmission and preserving neuronal tissue defines both the ceiling of these drugs and the case for addressing modifiable risk decades earlier.
Key Points
- Cholinesterase inhibitors produce small, measurable gains on cognitive scales
- Symptomatic benefit does not slow underlying neurodegenerative progression
- Statistical improvement may not translate to meaningful daily function
Longevity Analysis
Drugs that amplify a remaining neurotransmitter signal cannot compensate for neurons already lost, which places the decisive leverage years or decades before diagnosis — in vascular health, glucose regulation, sleep-dependent clearance of neural waste, and sustained physical loading. Interpreting a modest effect size correctly matters clinically: a statistically significant point change on a cognitive scale is not equivalent to preserved independence. The realistic role of these agents is to buy functional time, which is most valuable when paired with the metabolic and cerebrovascular work that determines how steeply the underlying trajectory falls.
Original published by Peter Attia MD, by Peter Attia.